Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients

陳榮楷, 吳秋文, 林增熙, 季匡華, 趙毅, 黃以信, 吳銘芳, 陳育民, 劉敏, 彭汪嘉康, 李壽東, 雷永耀

Research output: Contribution to journalArticlepeer-review


Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.
Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.
Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.
Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.
Translated title of the contributionCisplatin,5-Fluorouracil,Leucovorin治療頑固性胃癌
Original languageEnglish
Pages (from-to)255-262
Number of pages8
Issue number3
Publication statusPublished - 1994
Externally publishedYes


  • Cisplatin
  • 5-Fluorouracil
  • 頑固性胃癌
  • leucovorin
  • Fluorouracil


Dive into the research topics of 'Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients'. Together they form a unique fingerprint.

Cite this